Non-invasive genetic testing pushes tumor treatment into a "niche era"

Recently, Huada Pharmaceutical, a subsidiary of Huada Gene, officially released OseqTM-T, the first tumor genetic testing service based on high-throughput sequencing technology in China. It is reported that the service can provide information on genetic mutations in cancer patients, combined with information on pharmacogenomics.

Release date: 2014-09-17

Recently, Huada Pharmaceutical, a subsidiary of Huada Gene, officially released OseqTM-T, the first tumor genetic testing service based on high-throughput sequencing technology in China. It is reported that the service can provide information on gene mutations in cancer patients, combined with information on pharmacogenomics, to assist clinicians in selecting appropriate treatments for cancer patients, and to develop a comprehensive treatment plan.
Treatment "Because of the human cause"
The therapeutic effect of tumor therapeutic drugs is closely related to the mutations in the tumor genome of patients. A large number of studies have confirmed that accurate classification of tumors based on gene mutations is more conducive to individualized treatment of cancer patients, especially before drug administration. Related gene detection will enable patients to select the appropriate drug "due to human timing."
According to Li Yingrui, CEO of Huada Technology, since the first time scientists in the United States decoded the complete genome of patients with acute myeloid leukemia in 2008, laboratories in various countries scrambled to produce their own tumor samples for many years, and then found a large number of New tumor gene.
However, for a tumor patient, the occurrence, development, treatment, recurrence and metastasis of the tumor, and even the therapeutic effect of the tumor are closely related to the mutation of the tumor genome of the patient. These genetic variants appear in different types of tumors, such as: The mTOR signaling pathway gene is mutated in kidney cancer, lung cancer and colorectal cancer. Targeted drugs targeting signal pathway-related genes have become the current research and development hotspots.
Li Yingrui pointed out that genetic mutations in tumor cells are typical "positive choices" - as long as the tumor can maintain the basic biological functions of proliferation, the more mutations at other loci, the better, because the tumor cells need to constantly escape various factors and Regulatory mechanism. "If you remove each cell from the tumor and examine the genome of each cell, you will find that each genome is not exactly the same, which is different from normal tissue cells and has a high degree of 'heterogeneity'."
Challenge traditional pathological diagnosis
For this reason, the traditional pathological diagnosis has the drawback that it is difficult to overcome, that is, the pathological slice can only be a part of the tumor cells at a certain time point, and the difference between the tumor cells is very large. "Maybe in genomic diagnosis, a patient actually has 3 different tumors, but the pathological diagnosis can only diagnose one type because of the limitation of the slice. This is a short plate of the tumor diagnosis system, which may cause serious The consequences." Li Yingrui said.
It is reported that OseqTM-T testing products are completely developed independently by Huada Medical, and have applied for a number of patents. The technology uses high-throughput sequencing to perform related gene analysis on cancer tissues from tumor patients, and can detect 508 tumors at one time. Related genes, interpret 88 kinds of oncology drugs, comprehensively, systematically and accurately interpret the relationship between tumor drugs and genes, and assist doctors in selecting appropriate therapeutic drugs, formulating individualized treatment plans and prolonging patients' survival according to individual differences of patients. Time to improve the quality of life.
According to reports, on the basis of OseqTM-T, Huada Medical will also launch OseqTM-ctDNA, a non-invasive tumor gene detection product based on high-throughput sequencing technology to detect ctDNA (circulating tumor DNA) in blood, which can achieve early non-invasive tumors. Detection, individualized medication guidance, recurrence monitoring, etc. OseqTM-ctDNA allows for ultra-early, non-invasive detection of a variety of common high-risk cancers such as lung cancer, breast cancer, colorectal cancer, stomach cancer, thyroid cancer, and prostate cancer by extracting peripheral blood from the subject. The service will promote the individualized treatment of cancer into the era of non-invasive genetic testing.

Source: Medical Worker Online

Cargo Control Hardware

Cargo Control Hardware

We supply Cargo Control parts and accessories for your trailer when you need them . We have Adjustable Cargo Bar, Antiluce Fastener, hings, handles, latches, rivets and drill bits. We also have cargo straps, rollers, brackets, toolboxes, locks, floor screws and more.

96811_W4


Adjustable Cargo Bar, Antiluce Fastener, Shoring Bar, Jack Bar

Ningbo Yokelink Machinery Co.,Limited , https://www.yokelink.com